-
-
Igniting the Spark – Guangdong Launches Pilot Project for Eradicating Viral Hepatitis in Villages
2023-05-17Source:People's Daily -
On the morning of May 16th, the first pilot project in Guangdong, the "Spark Project" for eradicating the hazards of viral hepatitis in Jun'an Town, Shunde District, Foshan City, was officially launched. As a manufacturer of hepatitis B vaccines, Amyson Vaccine Co., Ltd. donated 40,000 doses of hepatitis B vaccine on-site.
-
-
-
Confidence in China's Economy | Jia Shaojun, Executive President and Board member of AIM Vaccine: Innovative Measures Enable Private Enterprises to Improve Quality and Efficiency
2023-03-17Source:Xinhua -
Jia Shaojun, Executive President and Board member of AIM Vaccine, said that technological innovation is also one of the driving forces for the development of vaccines companies. AIM Vaccine needs to have one or more well-received products in the pursuit of a great company and great companies can only be made by great products. Both the company’s confidence and motivation lie in this belief.
-
-
-
AIM Vaccine: Bivalent Delta+Omicron BA.5 COVID-19 mRNA vaccine has been approved for Phase III clinical trial in Pakistan
2023-03-14Source:Cailian Press -
AIM Vaccine announced that its upgrade product, bivalent Delta+Omicron BA.5 COVID-19 mRNA vaccine, has been officially approved for Phase III clinical trial in Pakistan.
-
-
-
Upgradation of COVID-19 vaccine: AIM Vaccine’s bivalent Delta+Omicron BA.5 mRNA vaccine has been approved for Phase III clinical trial in Pakistan
2023-03-14Source:Finance.china.com.cn -
Domestic leader in mRNA vaccine development, AIM Vaccine (06660.HK), is fully prepared to drive the upgradation of COVID-19 vaccines. According to the company's latest announcement, its bivalent Delta+Omicron BA.5 mRNA vaccine has been approved for Phase III clinical trial in Pakistan. Previously conducted clinical studies in China have proved good safety. Outcomes of virus neutralization assay showed that the vaccine candidate can induce high levels of neutralizing antibodies against Delta, Omicron BA.5, BQ.1 and XBB variants of SARS-nCoV-2.
-
-
-
AIM Vaccine shows intentions in A stock market with promising prospects of mRNA technology
2023-03-09Source:Cailian Press -
According to the latest announcement released by AIM Vaccine on March the 8th, the company plans to issue non-publicly traded RMB ordinary shares (i.e. domestic shares and/or non-publicly traded foreign shares) based on specific authorization. The funds raised will be used for constructing new production facilities for bivalent EV71-CA16 HFMD vaccines, developing COVID-19 variant mRNA vaccines (including but not limited to monovalent and multivalent vaccines targeting Omicron BA.5) and multivalent pneumococcal conjugate vaccines in the pipeline, supplementing operational capital, and for general corporate purposes.
According to market analysts, the domestic shares issued by AIM Vaccine in this targeted offering can only exit through A-shares in the future, indicating a clear sign of the company's intentions for an A-share listing.
-
-
-
AIM Vaccine: Two COVID-19 mRNA vaccines obtained clinical approval in Pakistan
2023-02-16Source:Cailian Press -
AIM Vaccine announced that two candidates of COVID-19 mRNA vaccine were approved for clinical trials in Pakistan. One targeting SARS-nCoV-2 mutant is approved for Phase I clinical trial, while the other targeting original COVID-19 virus is approved for Phase III clinical trial of sequential booster vaccination.
-